LIBTAYO

PeakmAb

cemiplimab-rwlc

BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
34

Mechanism of Action

PD-1 ligands PD-L1 and PD-L2 to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…

Clinical Trials (5)

NCT07433673Phase 2Recruiting

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Started Aug 2026
20 enrolled
Colon and Rectal Cancer
NCT06449313Phase 2Recruiting

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Started Apr 2026
21 enrolled
Non-small Cell Lung Cancer Stage III
NCT07234058Phase 2Not Yet Recruiting

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

Started Feb 2026
126 enrolled
Pleural Mesotheliomas
NCT07058012Phase 2Not Yet Recruiting

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Started Aug 2025
79 enrolled
Colo-rectal Cancer
NCT06902376Phase 1Recruiting

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Started Jun 2025
12 enrolled
Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors